Watch AGIO. Know when insiders buy.
One email the day a filing lands. Free.
AGIO
AGIOS PHARMACEUTICALS, INC.
37.18
+0.54 +1.47%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
53
WATCH · shorts 53
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
1 / 0
buys / sells · latest disclosed Sep 10
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.2BP/E —DIV YIELD —FCF YIELD -16.45%REV TTM $98.3M +140.6%NET INCOME −$411.3M −163.3%NET CASH —52W 22.34 – 45.49SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $44.7M | +259.3% | 93.3% | −$110.6M | −$100.7M | — | -1.69 | −$57.3M | $1.2M | −$58.5M | Jul 30 |
| Q1 2026 · Mar 31 | $20.7M | +137.7% | 93.6% | −$110M | −$99.1M | — | -1.69 | −$118.9M | $769K | −$119.7M | Jul 30 |
| Q4 2025 · Dec 31derived | $20M | +86.1% | 90.6% | −$121.6M | −$108M | — | -1.85 | −$96.2M | $1.1M | −$97.3M | Feb 12 |
| Q3 2025 · Sep 30 | $12.9M | +43.7% | 87.0% | −$116.9M | −$103.4M | −110.9% | -1.78 | −$88.2M | $1.6M | −$89.7M | Oct 30 |
| Q2 2025 · Jun 30 | $12.5M | +44.6% | 86.3% | −$127.1M | −$112M | — | -1.93 | −$77.1M | $875K | −$78M | Jul 30 |
| Q1 2025 · Mar 31 | $8.7M | +6.6% | 87.6% | −$106.6M | −$89.3M | — | -1.55 | −$111.5M | $766K | −$112.3M | Jul 30 |
| Q4 2024 · Dec 31derived | $10.7M | +51.1% | 88.3% | −$125M | −$96.5M | — | -1.74 | −$133.2M | $967K | −$134.1M | Feb 12 |
| Q3 2024 · Sep 30 | $9M | +21.2% | 91.3% | −$102.8M | $947.9M | — | 16.22 | −$84.2M | $419K | −$84.6M | Oct 30 |
| Q2 2024 · Jun 30 | $8.6M | — | 82.6% | −$105.8M | −$96.1M | — | -1.69 | −$72.6M | $158K | −$72.7M | Oct 30 |
| Q1 2024 · Mar 31 | $8.2M | — | 92.3% | −$92.1M | −$81.5M | — | -1.45 | −$99.9M | $141K | −$100M | Oct 30 |
| Q4 2023 · Dec 31derived | $7.1M | — | 91.7% | −$106.3M | −$95.9M | — | -1.72 | −$72.5M | $234K | −$72.7M | Feb 12 |
| Q3 2023 · Sep 30 | $7.4M | — | 91.4% | −$100.9M | −$91.3M | — | -1.64 | −$61.6M | $369K | −$62M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $54M | 88.3% | −$472.1M | −$412.8M | -764.0% | -7.12 | −$373M | $4.3M | −$377.3M | — | — |
| FY2024 · to Dec 31 | $36.5M | 88.6% | −$425.7M | $673.7M | 1845.9% | 11.64 | −$389.8M | $1.7M | −$391.5M | — | — |
| FY2023 · to Dec 31 | $26.8M | 89.3% | −$391.5M | −$352.1M | -1312.6% | -6.33 | −$296.1M | $999K | −$297.1M | — | — |
| FY2022 · to Dec 31 | $14.2M | 88.0% | −$389M | −$231.8M | -1627.8% | -4.23 | −$309.5M | $4.9M | −$314.4M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$378.4M | $1.6B | — | 26.55 | −$407.3M | $5.7M | −$413.1M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$335.9M | −$327.4M | — | -4.74 | −$290.8M | $14.1M | −$304.9M | — | — |
Every number comes from AGIOS PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.